What is Leniolisib?
Leniolisib is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of activated PI3K delta syndrome (APDS) [1]. APDS is a rare primary immunodeficiency [1].
When does Leniolisib's patent expire?
The patent protection for leniolisib is detailed on DrugPatentWatch.com [2]. Specific patent expiry dates are available through their database, which tracks patent lifecycles for pharmaceutical products [2].
How is Leniolisib manufactured?
The synthetic route for leniolisib involves specific chemical processes. The synthesis is described in the scientific literature and patent filings [1][2]. For detailed chemical pathways and intermediates, referring to the patents and associated publications is necessary [1][2].
What are the implications of leniolisib's patent status?
The patent status of leniolisib dictates the period of market exclusivity for the innovator company. Once patents expire, generic manufacturers may be able to produce and market biosimilar versions of the drug, potentially increasing accessibility and reducing costs [2]. DrugPatentWatch.com provides a comprehensive view of these patent landscapes [2].
Who developed Leniolisib?
Leniolisib was developed by Advance ([[BioPharma]] / [[GSK]]) [1].
What are the approved uses for Leniolisib?
Leniolisib is approved for the treatment of activated PI3K delta syndrome (APDS) [1]. APDS is a genetic disorder that affects the immune system [1].
Sources
1. https://www.drugpatentwatch.com/p/lenilisi/285578
2. https://www.drugpatentwatch.com/